论文部分内容阅读
为评价用阿克拉霉素A(ACR)治疗骨髓增生异常综合征(MDS)的可能性,进行了本研究。材料和方法治疗对象为按FAB标准诊断的4例MDS患者,其应用ACR治疗前的情况是,例2用ACR前曾用小剂量阿糖胞苷(Ara-C)无效却出现了明显的骨髓抑制,余3例均为初治。例4并发坏疽性脓皮病,并有染色体异常(8三体)。
This study was conducted to evaluate the possibility of treating myelodysplastic syndrome (MDS) with aclacinomycin A (ACR). MATERIALS AND METHODS: Four patients with MDS diagnosed according to FAB criteria were treated with ACR before treatment. Case 2 showed significant bone marrow rejection with a small dose of Ara-C before ACR Inhibition, more than 3 cases were naive. Example 4 concurrent pyoderma gangrenosum, and chromosomal abnormalities (trisomy 8).